Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 093 JPY -0.94%
Market Cap: 6.5T JPY
Have any thoughts about
Takeda Pharmaceutical Co Ltd?
Write Note

Takeda Pharmaceutical Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Takeda Pharmaceutical Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Takeda Pharmaceutical Co Ltd
TSE:4502
Depreciation & Amortization
ÂĄ758.5B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
Depreciation & Amortization
ÂĄ64.4B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
6%
Otsuka Holdings Co Ltd
TSE:4578
Depreciation & Amortization
ÂĄ107.9B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
7%
S
Shionogi & Co Ltd
TSE:4507
Depreciation & Amortization
ÂĄ19.7B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
3%
Chugai Pharmaceutical Co Ltd
TSE:4519
Depreciation & Amortization
ÂĄ31.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Depreciation & Amortization
ÂĄ184.9B
CAGR 3-Years
36%
CAGR 5-Years
23%
CAGR 10-Years
11%
No Stocks Found

Takeda Pharmaceutical Co Ltd
Glance View

Market Cap
6.5T JPY
Industry
Pharmaceuticals

Takeda Pharmaceutical Co. Ltd. stands as a formidable player in the global healthcare landscape, firmly established as Japan's largest pharmaceutical company. Founded in 1781, Takeda has built a rich legacy of innovation and patient-centricity, evolving from a traditional medicine distributor into a leader in biopharmaceuticals. The company primarily focuses on therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases, thus targeting critical health challenges faced by patients worldwide. Takeda's commitment to research and development, underscored by significant investments, facilitates the discovery of new treatments and the enhancement of existing therapies. This forward momentum is particularly noteworthy as it aligns with the growing demand for advanced medications and biologics, positioning Takeda favorably in a competitive market. In recent years, Takeda has strategically expanded its global footprint through key acquisitions, most notably the purchase of Shire in 2019, which significantly enhanced its portfolio in rare diseases. For investors, this positions Takeda not just as a pharmaceutical giant, but as an agile and innovative entity eager to meet the evolving needs of healthcare. With a robust pipeline that promises a mix of newly launched therapeutics and a focus on sustainable growth, Takeda showcases its resilience in navigating the pharmaceutical industry's challenges. The company's dedication to fostering partnerships, along with its ethical approach to business, further strengthens its reputation as a trustworthy investment in the pharmaceutical sector. For investors looking for a blend of historical stability and future potential in a company deeply committed to health and well-being, Takeda stands out as a compelling choice.

Intrinsic Value
5 344.29 JPY
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Takeda Pharmaceutical Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
758.5B JPY

Based on the financial report for Sep 30, 2024, Takeda Pharmaceutical Co Ltd's Depreciation & Amortization amounts to 758.5B JPY.

What is Takeda Pharmaceutical Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
13%

Over the last year, the Depreciation & Amortization growth was 10%. The average annual Depreciation & Amortization growth rates for Takeda Pharmaceutical Co Ltd have been 10% over the past three years , 7% over the past five years , and 13% over the past ten years .

Back to Top